Ownership history in Euclidean Capital LLC Β· 21 quarters on record
This page tracks every 13F SEC filing in which Euclidean Capital LLC reported a position in ORIC PHARMACEUTICALS INC (ORIC). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Euclidean Capital LLC outperformed the S&P 500 by +25.7% annually on this ORIC position. Timing score: 80% (4/5 decisions correct). Average cost basis: $29.76. Maximum drawdown during holding period: β90.5%.
π₯ Exceptional β beat the S&P 500 by 25.7% per year on this position.
11 quarters analyzed
π― Smart timing β consistently buying dips and trimming near peaks.
4 of 5 add/trim decisions correct
Best entry: $6.05 (2023 Q3) Β· Worst: $33.85 (2020 Q4)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
2 adds Β· 3 trims. Bought during 1 of 12 down-price quarters. π Predominantly trimming β distribution phase.
π Euclidean Capital LLC has been actively increasing its ORIC allocation β a bullish signal from insiders.
Currently 2.19% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size